Non-invasive grading of astrocytic tumours from the relative contents of myo-inositol and glycine measured by in vivo MRS

JBR-BTR

Volumn 94, Issue 6, 2011, Pages 319-329

  Candiota, A P ^a,b   Majos C ^a,c   Julia Sape M ^a,b   Cabanas M ^a,b   Acebes, J J ^a,c   Moreno Torres, A ^a,d   Griffiths, J R ^e   Arus C ^a,b  

^a BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d Cetir Centre Mèdic SL Unitat Esplugues   (Spain)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Astrocytoma Magnetic resonance (MR); spectroscopy

Indexed keywords

GLYCINE; INOSITOL; PERCHLORIC ACID; CHOLINE; CONTRAST MEDIUM; CREATINE; DIAGNOSTIC AGENT;

ARTICLE; ASTROCYTOMA; CANCER GRADING; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; TUMOR BIOPSY; ANALYSIS OF VARIANCE; BIOPSY; BRAIN TUMOR; IMAGE QUALITY; METABOLISM; METHODOLOGY; NONPARAMETRIC TEST; PATHOLOGY;

ANALYSIS OF VARIANCE; ASTROCYTOMA; BIOPSY; BRAIN NEOPLASMS; CHOLINE; CONTRAST MEDIA; CREATINE; GLYCINE; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASM GRADING; PERCHLORIC ACID; PHANTOMS, IMAGING; STATISTICS, NONPARAMETRIC;

EID: 84859413329     PISSN: 17802393     EISSN: None     Source Type: Journal    
DOI: 10.5334/jbr-btr.698     Document Type: Article

References (54)

1. Danielsen E.R., Ross B.: Magnetic resonance spectroscopy diagnosis of neurological diseases. Marcel Dekker Inc, New York, 1999.
2. van der Graaf M.: In vivo magnetic resonance spectroscopy: basic methodology and clinical applications. Eur Biophys J, 2010, 39: 527-540.
3. Oh J., Henry RG., Pirzkall A., Lu Y., Li X., Catalaa I., Chang S., Dillon W.P., Nelson S.J.: Survival Analysis in Patients With Glioblastoma Multi - forme: Predictive Value of Choline-to-NAcetylaspartate Index, Apparent Diffusion Coefficient, and Relative Cerebral Blood Volume J Magn Reson Imaging, 2004, 19: 546-554.
4. Fellows G.A., Wright A.J., Sibtain N.A., Rich P., Opstad K.S., McIntyre D.J., Bell B.A., Griffiths J.R., Howe F.A.: Combined use of neuroradiology and 1H-MR spectroscopy may provide an intervention limiting diagnosis of glioblastoma multiforme. J Magn Reson Imaging, 2010, 32: 1038-1044.
5. Stewart B.W., Kleihues P.: World Cancer Report. IARC Press, Lyon, 2003.
6. Chamberlain M.C., Kormanik P.A.: Practical guidelines for the treatment of malignant gliomas. West J Med, 1998, 168: 114-120
7. Coons S.W., Johnson P.C., Scheithauer B.W., Yates A.J., Pearl D.K.: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer, 1997: 1381-1393.
8. Law M., Yang S., Wang H., Babb J.S., Johnson G., Cha S., Knopp E.A., Zagzag D.: Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol, 2003, 24: 1989-1998.
9. Julià-Sapé M., Acosta D., Majós C., Moreno-Torres A., Wesseling P., Acebes J.J., Griffiths J.R., Arús C.: Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database. J Neuro surg, 2006. 105: 6-14.
10. De Edelenyi F.S., Rubin C., Estève F., Grand S., Décorps M., Lefournier V., Le Bas J.F., Rémy C.: A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images. Nat Med, 2000, 6: 1287-1289.
11. Tate A.R., Acosta D., Julià-Sapé M. et al: Development of a decision support system for diagnosis and grading of brain tumors using in vivo magnetic resonance single voxel spectra. NMR Biomed, 2006, 19: 411-434.
12. Pérez-Ruiz A., Julià-Sapé M., Mercadal G., Olier I., Majós C., Arús C.: The INTERPRET Decision-Support System version 3.0 for evaluation of Magnetic Resonance Spectroscopy data from human brain tumours and other abnormal brain masses. BMC Bioinformatics, 2010, 11: 581.
13. Kugel H., Heindel W., Ernestus R.I., Bunke J., du Mesnil R., Friedmann G.: Human brain tumors: spectral patterns detected with localized H-1 MR Spectro scopy. Radiology, 1992, 183: 701-709.
14. Ott D., Hennig J., Ernst T.: Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology, 1993, 186: 745-752.
15. Mader I., Roser W., Hagberg G.K., Schneider M., Sauter R., Seelig J., Radue E.W., Steinbrich W.: Proton chemical shift imaging, metabolic maps, and single voxel spectroscopy of glial brain tumors. MAGMA, 1996, 4: 139-150.
16. Majós C., Alonso J., Aguilera C., Serrallonga M., Pérez-Martín J., Acebes J.J., Arús C., Gili J.: Proton magnetic resonance spectroscopy (1H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol, 2003, 13: 582-591.
17. Castillo M., Smith J.K., Kwock L.: Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol, 2000 21: 1645-1649.
18. Soares D.P., Law M.: Magnetic Resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol, 2009 64: 12-21.
19. Ernst T.H., Hennig J.: Coupling effects in volume selective 1H spectroscopy of major brain metabolites. Magn Reson Med, 1991: 21: 82-96.
20. Barba I., Moreno A., Martínez-Pérez I., Tate A.R., Cabañas M.E., Baquero M., Capdevila A., Arús C.: Magnetic resonance spectroscopy of brain hemangiopericytomas: high myoinositol concentrations and discrimination from meningiomas. J Neurosurg, 2001, 94: 55-60.
21. Candiota A.P., Majós C., Julià-Sapé M., Cabañas M., Mercadal G., Acebes J.J., Moreno-Torres A., Griffiths J.R., Arús C.: M-Inositol and glycine content measurement for grading astrocytic tumours with in vivo MRS. In: Magnetic Resonance Materials in Physics, Biology and Medicine (MAGMA) 18 supplement 7 (Book of Abstracts ESMRMB, 2005 22nd Annual Scientific Meeting Basle/CH, Sept. 15-18, 2005): pp S 193, 2005. DOI: 10.1007/s10334-005-0002-2.
22. Rèmy C., Arús C., Ziegler A., Lai E.S., Moreno A., Le Fur Y., Decòrps M.: In vivo, ex vivo, and in vitro one- and two-dimensional nuclear magnetic resonance spectroscopy of an intra - cerebral glioma in rat brain: assignment of resonances. J Neurochem, 1994, 62: 166-179.
23. Candiota A.P., Majós C., Bassols A., Cabanas M.E., Acebes J.J., Quintero M.R., Arús C.: Assignment of the 2.03 ppm resonance in in vivo 1H MRS of human brain tumour cystic fluid: contribution of macromolecules Magn Reson Mater Phys MAGMA, 2004, 17: 36-46.
24. Candiota A.P.: PhD thesis (2004) (Contribució a la millora del diagnòstic i de la valoració pronòstica de tumors cerebrals humans) http://www.tdx.cesca.es/TDX-0714105-173443/.
25. Julia-Sape M., Acosta D., Mier M., Arus C., Watson D.; INTERPRET consortium: A multi-centre, web-accessible and quality control-checked database of in vivo MR spectra of brain tumour patients. MAGMA, 2006, 19: 22-33.
26. Coates H.B., McLauchlan K.A., Campbell I.D., McColl C.E.: Proton spin lattice relaxation time measurements at 90MHz and 270 MHz. Bio - chim Biophys Acta, 1973, 310: 1-10.
27. Frahm J., Bruhn H., Gyngell M.L., Merboldt K.D., Hänicke W., Sauter R.: Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magn Reson Med, 1989, 11: 47-63.
28. Choi C.G., Frahm J.: Localized proton MRS of the human hippocampus: metabolite concentrations and relaxation times. Magn Reson Med, 1999, 41: 204-207.
29. van der Graaf M., Julià -Sapé M., Howe F.A., Ziegler A., Majós C., Moreno-Torres A., Rijpkema M., Acosta D., Opstad K.S., van der Meulen Y.M., Arús C., Heerschap A.: MRS quality assessment in a multicentre study on MRS-based classification of brain tumours. NMR Biomed, 2006, 21: 148-158.
30. Kim H., Wild J.M., Allen P.S.: Strategy for the Spectral Filtering of Myo-Inositol and Other Strongly Coupled Spins. Magn Reson Med, 2004, 51: 263-272.
31. Prescot A.P., deB Frederick B., Wang L., Brown J., Jensen J.E., Kaufman M.J., and Renshaw P.F.: In vivo Detection of Brain Glycine with Echo-Time-Averaged 1H Magnetic Resonance Spectroscopy at 4.0 T. Magn Reson Med, 2006, 55: 681-686.
32. Choi C., Bhardwaj P.P., Seres P., Kalra S., Tibbo P.G., Coupland N.J.: Measurement of glycine in human brain by triple refocusing 1H-MRS in vivo at 3.0T. Magn Reson Med, 2008, 59: 59-64.
33. Gambarota G., Mekle R., Xin L., Hergt M., van der Zwaag W., Krueger G., Gruetter R.: In vivo measurement of glycine with short echotime 1H MRS in human brain at 7 T. MAGMA, 2009, 22: 1-4.
34. Bobek-Billewicz B., Hebda A., Stasik-Pres G., Majchrzak K., Zmuda E., Trojanowska A.: Measurement of glycine in a brain and brain tumors by means of 1H MRS. Folia Neuropathol, 2010, 48: 190-199.
35. Hattingen E., Lanfermann H., Quick J., Franz K., Zanella F.E., Pilatus U.: 1H MR spectroscopic imaging with short and long echo time to discriminate glycine in glial tumours. MAGMA, 2009, 22: 33-41.
36. Kaufman M.J., Prescot A.P., Ongur D., Evins A.E., Barros T.L., Medeiros C.L., Covell J., Wang L., Fava M., Renshaw P.F.: Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study. Psychiatry Res, 2009: 173: 143-149.
37. Majós C., Julià-Sapé M., Alonso J., Serrallonga M., Aguilera C., Acebes J.J., Arús C., Gili J.: Tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. AJNR Am J Neuroradiol, 2004, 25: 1696-704.
38. Majós C., Julià-Sapé M. et al.: Proton magnetic resonance spectroscopy provides revelant prognostic information in high-grade astrocytomas. AJNR, 2011, 32: 74-80.
39. García-Gómez J.M., Tortajada S., Vidal C., Julià-Sapé M., Luts J., Moreno-Torres A., Van Huffel S., Arús C., Robles M.: The effect of combining two echo times in automatic brain tumor classification by MRS. NMR Biomed, 2008, 21: 1112-1125.
40. Kleihues P., Ohgaki H.: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncology, 1999, 1: 44-51.
41. Mischel P.S., Nelson S.F., Cloughesy T.F.: Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther, 2003, 2: 242-247.
42. Martinez-Bisbal M.C., Marti-Bonmati L., Piquer J., Revert A., Ferrer P., Llacer J.L., Piotto M., Assemat O., Celda B.: 1H and 13C HRMAS spectroscopy of intact biopsy samples ex vivo and in vivo 1H MRS study of human high grade gliomas. NMR Biomed, 2004, 17: 191-205.
43. Peeling J., Sutherland G.: High-resolution 1H NMR spectroscopy studies of extracts of human cerebral neoplasms. Magn Reson Med, 1992, 24: 123-136
44. Kinoshita Y., Yokota A.: Absolute concentrations of metabolites inhuman brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed, 1997, 10: 2-12.
45. Roda J.M., Pascual J.M., Carceller F., González-Llanos F., Pérez-Higueras A., Solivera J., Barrios L., Cerdán S.: Nonhistological diagnosis of human cerebral tumors by 1H magnetic resonance spectroscopy and amino acid analysis. Clin Cancer Res, 2000, 6: 3983-3993.
46. Carpinelli G., Carapella C.M., Palombi L., Raus L., Caroli F., Podo F.: Differentiation of glioblastoma multiforme from astrocytomas by in vitro 1H MRS analysis of human brain tumors. Anticancer Res, 1996, 16: 1559-1563.
47. Righi V., Mucci A., Schenetti L., Bacci A., Agati R., Leonardi M., Schiavina R., Martorana G., Liguori G., Calabrese C., Boschetti E., Bonora S., Tugnoli V.: Identification of mobile lipids in human cancer tissues by ex vivo diffusion edited HR-MAS MRS. Oncol Rep, 2009 22: 1493-1496.
48. Wright A.J., Fellows G.A., Griffiths J.R., Wilson M., Bell B.A., Howe F.A.: Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers. Mol Cancer., 2010, 9: 66.
49. Lehnhardt F.G., Bock C., Röhn G., Ernestus R.I., Hoehn M.: Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed, 2005, 18: 371-382.
50. Davies N.P., Wilson M., Natarajan K., Sun Y., MacPherson L., Brundler M.A., Arvanitis TN., Grundy R.G., Peet A.C.: Non-invasive detection of glycine as a biomarker of malignancy in childhood brain tumours using in-vivo 1H MRS at 1.5 tesla confirmed by ex-vivo high-resolution magic-angle spinning NMR. NMR Biomed, 2010, 23: 80-87.
51. Zhang K., Weinberg J.M., Venkatachalam M.A., Dong Z.: Glycine protection of PC-12 cells against injury by ATP-depletion. Neurochem Res, 2003, 28: 893-901.
52. Nishimura Y., Lemasters J.J.: Glycine blocks opening of a death channel in cultured hepatic sinusoidal endothelial cells during chemical hypoxia. Cell Death Differ, 2001, 8: 850-858.
53. Ruiz-Meana M., Pina P., Garcia-Dorado D., Rodriguez-Sinovas A., Barba I., Miro-Casas E., Mirabet M., Soler-Soler J.: Glycine protects cardiomyocytes against lethal reoxygenation injury by inhibiting mitochondrial permeability transition. J Physiol, 2004, 558(Pt 3): 873-882.
54. Valverde D., Quintero M.R., Candiota A.P., Badiella L.l., Cabañas M.E., Arús C.: Analysis of the changes in the 1H NMR PCA extract pattern of C6 cells with growth curve stage. NMR Biomed, 2006, 19: 223-230.